Galecto, INC Form 4 insider transactions

Andrew Cheng, a Director of Galecto, Inc., received 30,350 shares of common stock on August 12, 2026.

Garrett Winslow, General Counsel of Damora Therapeutics, Inc., reported transactions involving the settlement of restricted stock units and the subsequent sale of shares to cover tax obligations.

Damora Therapeutics' President and CEO, Jennifer Jarrett, acquired 500,000 restricted stock units and 1,500,000 stock options on March 30, 2026.

Damora Therapeutics' General Counsel, Garrett Winslow, was granted 250,000 stock options with an exercise price of $23.05, vesting over four years.

Damora Therapeutics Director Cameron Turtle was granted 37,313 stock options with an exercise price of $23.05, vesting monthly through March 2029.

Damora Therapeutics, Inc. Director Michael Landsittel was granted 37,313 stock options with an exercise price of $23.05, vesting through March 2029.

Peter Harwin, a director and manager of Fairmount Funds, received stock options for 37,313 shares of Damora Therapeutics common stock.

Damora Therapeutics Director Christopher W. Cain received 37,313 stock options with a $23.05 exercise price, vesting through March 2029.

Julianne Bruno, a Director at Damora Therapeutics, Inc., was granted 37,313 stock options with an exercise price of $23.05.

Galecto Director Julianne Bruno converted 129 shares of Series C Preferred Stock into 129,000 shares of Common Stock following stockholder approval.

Fairmount Funds Management and affiliated entities converted Series C Preferred Stock into 8.7 million shares of Galecto, Inc. common stock following stockholder approval.

Galecto, Inc.'s Chief Operating Officer, Sherwin Sattarzadeh, was granted 190,376 restricted stock units and options for 444,209 shares, aligning executive incentives with shareholder value.

Galecto's Chief Medical Officer, Hewes L. Becker, received grants of 264,629 restricted stock units and options to purchase 528,603 shares of common stock.

Galecto, Inc. CEO Hans T. Schambye reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Galecto Inc.'s General Counsel, Garrett Winslow, sold 255 shares of common stock to cover tax obligations following the vesting of 680 restricted stock units.

Galecto Inc.'s Chief Financial Officer, Lori Firmani, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Galecto, Inc. CEO Hans T. Schambye reported the pre-planned settlement of restricted stock units and a subsequent sale of shares to cover tax obligations on July 3, 2025.

Galecto Inc.'s General Counsel, Garrett Winslow, reported the settlement of restricted stock units and a subsequent sale of shares to cover tax obligations.

Galecto, Inc.'s Interim CFO, Lori Firmani, reported the vesting of 374 restricted stock units and a subsequent sale of 147 shares to cover tax obligations on July 3, 2025.

Galecto, Inc. Director Jayson Donald Alexander was granted 720 stock options with an exercise price of $3.22 per share following the company's 2025 Annual Meeting of Stockholders.

Galecto, Inc. Director Amit Munshi has reported the acquisition of 720 stock options at an exercise price of $3.22, granted on June 18, 2025, as part of the company's Non-Employee Director Compensation Policy.

Galecto, Inc. Director David Shapiro was granted 720 stock options with an exercise price of $3.22, vesting monthly over one year, as part of the company's non-employee director compensation policy.

Galecto, Inc. Director Anne Prener was granted 720 stock options with an exercise price of $3.22, effective June 18, 2025, as part of the company's non-employee director compensation policy.

Galecto, Inc. Director Amy B. Wechsler was granted 720 stock options with an exercise price of $3.22, effective June 18, 2025, as part of the company's Non-Employee Director Compensation Policy.

Galecto, Inc. Director Carl Goldfischer was granted 1,440 stock options with an exercise price of $3.22, vesting over one year, as part of the company's non-employee director compensation policy.

Garrett Winslow, General Counsel of Galecto, Inc., reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Interim CFO Lori Firmani reports the vesting and sale of Galecto, Inc. common stock to cover tax obligations, along with the grant of new stock options.

Matthew Kronmiller, EVP Strategy and CBO of Galecto, Inc., reports the acquisition of stock options.

Galecto, Inc. CEO Hans T. Schambye reports the vesting of restricted stock units, subsequent sale of shares for tax obligations, and grant of new stock options.

Director Amy B. Wechsler reports the acquisition of stock options in Galecto, Inc. related to her role on the Board of Directors.